EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

TOP ARTICLES

press releases Read more...

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

Revolution Medicines Inc Nasdaq RVMD a global commercialstage oncology company dedicated to discovering developing and delivering innovative medicines for patients with RASaddicted cancers today announced that the US Food and Drug Administration FDA has granted Breakthrough

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya Therapeutics Inc NASDAQ TNYA a clinicalstage biotechnology company with a mission to discover develop and deliver potentially curative therapies that address the underlying causes of heart disease

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

Agomab Therapeutics NV Agomab a clinicalstage biopharmaceutical company focused on fibroinflammation today announced positive results of the Phase study of AGMB in IPF patients

BioLife receives US patent for novel effervescent tablet technology for oral peptide delivery

BioLife announced today that the US Patent and Trademark Office has granted US Patent B for its novel oral peptide delivery technology via effervescent tablets It was developed for current and future peptide therapies for obesity diabetes and metabolic disorders

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

28 - 01

Sep 2026

LATEST NEWS Read more...

Asimov Partners with Sidewinder Therapeutics on Cell Line Development for Bispecific Antibody

Asimov has entered into a cell line development partnership with Sidewinder Therapeutics to support the development of a fourchain bispecific antibody candidate for solid tumour treatment

Sanofi and Cheplapharm Plan Strategic Partnership for Mature Medicines

Sanofi and Cheplapharm have announced plans to form a strategic partnership covering a selection of Sanofis mature medicines Under the proposed agreement Cheplapharm would acquire established

Renova Pharmaceuticals Launches First Three US Generic Products

Renova Pharmaceuticals has launched its first three generic products in the US marking a major milestone as the company moves from developing its product and regulatory pipeline to establishing a commercial presence in the US generics market

Community Clinical Research Joins PhaseWell Research to Expand CNS Clinical Trial Access in Te

PhaseWell Research has partnered with Community Clinical Research CCR in Austin Texas to strengthen its inpatient central nervous system CNS research capabilities and expand access to clinical trials across Texas

Sysmex Europe and Cytek Biosciences collaborate to expand access to advanced clinical flow cytometry

Sysmex Europe SE and Cytek Biosciences Inc have announced a strategic collaboration across more than a dozen European countries to improve clinical flow cytometry workflows and expand access to advanced diagnostic solutions

Ratio Therapeutics and RayzeBio enter collaboration to advance novel radiopharmaceutical programme

Ratio Therapeutics Inc has entered into a research collaboration and licence agreement with RayzeBio Inc to advance a new radiopharmaceutical programme focused on two undisclosed targets